Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Details) - Schedule of Segment Reporting Information, by Segment

v3.20.1
SEGMENT REPORTING (Details) - Schedule of Segment Reporting Information, by Segment - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Segment Reporting Information [Line Items]    
Research and development $ 4,926,714 $ 1,488,839
General and administrative 7,855,220 4,378,897
Depreciation and amortization 21,015  
Total operating expenses 12,802,949 5,875,671
Loss from Operations (12,802,949)  
Interest income 39,576  
Net loss (12,763,373) (5,869,548)
Preferred stock dividend (4,618) (10,541)
Net loss attributable to common stockholder (12,767,991) (5,880,089)
Non-controlling interest 1,427,813 0
Net loss attributable to BioSig Technologies, Inc. (11,340,178) $ (5,880,089)
Corporate Segment [Member]    
Segment Reporting Information [Line Items]    
Research and development 1,327,003  
General and administrative 3,819,438  
Depreciation and amortization 21,015  
Total operating expenses 5,167,456  
Loss from Operations (5,167,456)  
Interest income 25,411  
Net loss (5,142,045)  
Preferred stock dividend (4,618)  
Net loss attributable to common stockholder (5,146,663)  
Non-controlling interest 0  
Net loss attributable to BioSig Technologies, Inc. (5,146,663)  
ViralClear [Member]    
Segment Reporting Information [Line Items]    
Research and development 3,599,711  
General and administrative 4,035,782  
Depreciation and amortization 0  
Total operating expenses 7,635,493  
Loss from Operations (7,635,493)  
Interest income 14,165  
Net loss (7,621,328)  
Preferred stock dividend 0  
Net loss attributable to common stockholder (7,621,328)  
Non-controlling interest 1,427,813  
Net loss attributable to BioSig Technologies, Inc. $ (6,193,515)